A randomized phase II study of pemetrexed or RADOO1 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: Treatment rationale and protocol dynamics

Clinical Lung Cancer

Volumn 8, Issue 9, 2007, Pages 568-571

  Gridelli, Cesare ^a   Rossi, Antonio ^a   Morgillo, Floriana ^b   Bareschino, Maria Anna ^b   Maione, Paolo ^a   Di Maio, Massimo ^c   Ciardiello, Fortunato ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c N Giannettasio Hospital   (Italy)

Author keywords

Chemotherapy; Everolimus; Mammalian target of rapamycin; Targeted therapy

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; EVEROLIMUS; FOLIC ACID; PEMETREXED;

CANCER SURVIVAL; CLINICAL TRIAL; DISEASE CONTROL; DISEASE COURSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GERIATRIC PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; REVIEW; STATISTICAL ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 37349116089     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2007.n.045     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Gridelli C, Shepherd F. Chemotherapy for elderly patients with non-small-cell lung cancer: a review of the evidence. Chest 2005; 128:947-57.
3. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362-72.
4. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21:1383-9.
5. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061-7.
6. Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91:66-72.
7. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-53.
8. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non small cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005; 23:3125-37.
9. Shepherd FA, Dancey J, Ramlau R, et al. A prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-103.
10. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group [published correction appears in J Clin Oncol 2004; 22:209]. J Clin Oncol 2000; 18:2354-62.
11. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-97.
12. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
13. Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:4405-11.
14. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103:253-62.
15. Kozma SC, Thomas G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioassays 2002; 24:65-71.
16. Tang JM, He QY, Guo RX, et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006; 51:181-91.
17. Soria JC, Lee HY, Lee JL, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002; 8:1178-84.
18. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in nonsmall-cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004; 25:2053-9.
19. Proud CG. Regulation of mammalian translation factors by nutrients. Eur J Biochem 2002; 269:5338-49.
20. Peng T, Golub TR, Drenan R, et al. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino-acid and glucose deprivation. Mol Cell Biol 2002; 22:5575-84.
21. Beugnet A, Tee AR, Taylor PM, et al. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem J 2003; 372:555-66.
22. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64:36-42.
23. O'Reilly T, Vaxelaire J, Muller M, et al. In vivo activity of RAD001, an orally acrive rapamycin derivative, in experimental tumor models. Proc Am Soc Cancer Res 2002; 43:17 (Abstract 359).
24. Papadimitrakopoulou V, Soria JC, Douillard JY, et al. A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors. J Clin Oncol 2007; 25(18 suppl):406s (Abstract 7589).
25. Herson J, Carter SK. Calibrated phase II clinical trials in oncology. Stat Med 1986; 5:441-7.